Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

OM:NOBA
OM:NOBABanks

NOBA Bank Group (OM:NOBA): Reviewing Valuation Following Recent Share Price Momentum

NOBA Bank Group (OM:NOBA) has seen its stock fluctuate recently, catching the attention of investors looking for signals about the company's direction. Although there have been minor shifts in the past week and month, the current performance invites a closer look at its fundamentals. See our latest analysis for NOBA Bank Group. After a steady climb earlier in the year, NOBA Bank Group’s recent 1.33% uptick in share price has nudged momentum back in a positive direction, following a brief dip...
NasdaqGM:ISTR
NasdaqGM:ISTRBanks

Is Investar Holding Still Trading Below Fair Value After Its Strategic Acquisition?

Ever wondered if Investar Holding is trading for less than it’s really worth? Let’s dig into what the numbers and market buzz reveal about its current value. The stock has climbed 3.4% over the past month and is up 11.9% since the start of the year, signaling renewed investor interest and possibly shifting sentiment around its growth prospects. Recently, the company completed a strategic acquisition aimed at expanding its regional presence, which has caught the eye of both analysts and...
NasdaqCM:ELDN
NasdaqCM:ELDNBiotechs

Can Eledon Pharmaceuticals’ (ELDN) Mixed Kidney Trial Results Reshape Its Competitive Edge in Transplant Care?

In November 2025, Eledon Pharmaceuticals presented results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in kidney transplant recipients at the American Society of Nephrology's Kidney Week Annual Meeting. Although the primary endpoint did not meet statistical significance, the drug showed a promising safety profile and higher kidney function in some key patient subgroups compared to standard tacrolimus therapy. We'll explore how tegoprubart's...
NasdaqGS:AKRO
NasdaqGS:AKROBiotechs

Evaluating Akero Therapeutics (AKRO): Is the Current Valuation Justified After Recent Share Price Momentum?

Akero Therapeutics (AKRO) stock has been quietly trending higher this month, gaining roughly 16% despite little in the way of major news. Many investors are revisiting the company’s progress and recent momentum. See our latest analysis for Akero Therapeutics. Akero’s impressive 16% share price return this month builds on a strong year, with momentum clearly gaining steam. The stock has surged 92.5% year-to-date. While recent news has been quiet, long-term total shareholder returns have also...
NasdaqGM:GAMB
NasdaqGM:GAMBMedia

Has GAMB’s 54% Drop Created an Opportunity After Recent Regulatory Uncertainty?

Wondering if Gambling.com Group is a golden opportunity trading below its fair value, or if the recent turbulence has put the stock in the bargain bin? Let’s take a closer look at what is really behind the current price. Shares have slipped by 6.7% over the last week and are down a hefty 54.6% year-to-date, highlighting how much sentiment and perceived risk can shift for this stock. Ongoing discussions surrounding digital gambling legislation and increased competition in the affiliate...
ENXTPA:LR
ENXTPA:LRElectrical

Will Legrand’s (ENXTPA:LR) Growth Outlook Outweigh Mixed Demand Signals for Investors?

Legrand SA recently confirmed its full-year 2025 earnings guidance, projecting sales growth of 10% to 12% excluding currency effects, and reported nine-month sales of €6.97 billion with net income of €892.3 million. While the company highlighted ongoing growth and a positive outlook for data centres, attention has shifted to softer demand trends and the timing of future growth as quarterly sales growth missed some analyst expectations. We'll examine how Legrand's reaffirmed sales guidance...